Do analysts rate LLY or CPIX?

Eli Lilly and Company presently has a consensus price target of $1,227.00, suggesting a potential upside of 13.47%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, equities analysts clearly believe Eli Lilly and Company is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eli Lilly and Company 1 Sell rating(s) 4 Hold rating(s) 23 Buy rating(s) 2 Strong Buy rating(s) 2.87 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to LLY or CPIX?

In the previous week, Eli Lilly and Company had 150 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 154 mentions for Eli Lilly and Company and 4 mentions for Cumberland Pharmaceuticals. Eli Lilly and Company's average media sentiment score of 0.90 beat Cumberland Pharmaceuticals' score of 0.59 indicating that Eli Lilly and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eli Lilly and Company 83 Very Positive mention(s) 26 Positive mention(s) 36 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Positive Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CPIX or JNJ?

Johnson & Johnson has a consensus target price of $253.04, suggesting a potential upside of 13.17%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts plainly believe Johnson & Johnson is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Johnson & Johnson 0 Sell rating(s) 7 Hold rating(s) 20 Buy rating(s) 0 Strong Buy rating(s) 2.74

Does the media prefer CPIX or JNJ?

In the previous week, Johnson & Johnson had 85 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 89 mentions for Johnson & Johnson and 4 mentions for Cumberland Pharmaceuticals. Johnson & Johnson's average media sentiment score of 1.02 beat Cumberland Pharmaceuticals' score of 0.59 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Johnson & Johnson 60 Very Positive mention(s) 9 Positive mention(s) 11 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Positive

Do analysts rate CPIX or ABBV?

AbbVie has a consensus price target of $253.43, indicating a potential upside of 16.66%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AbbVie 0 Sell rating(s) 6 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 2.88

Does the media refer more to CPIX or ABBV?

In the previous week, AbbVie had 43 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 47 mentions for AbbVie and 4 mentions for Cumberland Pharmaceuticals. AbbVie's average media sentiment score of 0.92 beat Cumberland Pharmaceuticals' score of 0.59 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 28 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Do analysts rate CPIX or MRK?

Merck & Co., Inc. has a consensus price target of $128.18, suggesting a potential upside of 11.53%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Merck & Co., Inc. 0 Sell rating(s) 7 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.68

Does the media refer more to CPIX or MRK?

In the previous week, Merck & Co., Inc. had 60 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 64 mentions for Merck & Co., Inc. and 4 mentions for Cumberland Pharmaceuticals. Merck & Co., Inc.'s average media sentiment score of 1.03 beat Cumberland Pharmaceuticals' score of 0.59 indicating that Merck & Co., Inc. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merck & Co., Inc. 43 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Positive

Do analysts rate CPIX or PFE?

Pfizer has a consensus target price of $28.82, suggesting a potential upside of 13.64%. Given Pfizer's stronger consensus rating and higher possible upside, analysts plainly believe Pfizer is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pfizer 3 Sell rating(s) 11 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.20

Does the media prefer CPIX or PFE?

In the previous week, Pfizer had 77 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 81 mentions for Pfizer and 4 mentions for Cumberland Pharmaceuticals. Pfizer's average media sentiment score of 0.63 beat Cumberland Pharmaceuticals' score of 0.59 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 34 Very Positive mention(s) 17 Positive mention(s) 13 Neutral mention(s) 10 Negative mention(s) 7 Very Negative mention(s) Positive

Cumberland Pharmaceuticals (CPIX) Competitors

$5.61 -0.16 (-2.77%)

Closing price 04:00 PM Eastern

Extended Trading

$5.66 +0.05 (+0.98%)

As of 05:33 PM Eastern

Compare

CPIX vs. LLY, JNJ, ABBV, MRK, and PFE

Should you buy Cumberland Pharmaceuticals stock or one of its competitors? MarketBeat compares Cumberland Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cumberland Pharmaceuticals include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "pharmaceuticals" industry.

How does Cumberland Pharmaceuticals compare to Eli Lilly and Company?

Eli Lilly and Company (NYSE:LLY) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Eli Lilly and Company has a net margin of 34.98% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Eli Lilly and Company's return on equity of 105.77% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	34.98%	105.77%	23.76%
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Eli Lilly and Company presently has a consensus price target of $1,227.00, suggesting a potential upside of 13.47%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, equities analysts clearly believe Eli Lilly and Company is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Eli Lilly and Company had 150 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 154 mentions for Eli Lilly and Company and 4 mentions for Cumberland Pharmaceuticals. Eli Lilly and Company's average media sentiment score of 0.90 beat Cumberland Pharmaceuticals' score of 0.59 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	83 Very Positive mention(s)	26 Positive mention(s)	36 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Positive
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eli Lilly and Company has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$72.25B	14.09	$20.64B	$28.15	38.41
Cumberland Pharmaceuticals	$41.94M	2.00	-$2.84M	-$0.49	N/A

Eli Lilly and Company has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Summary

Eli Lilly and Company beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Johnson & Johnson?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Johnson & Johnson has a net margin of 21.83% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Johnson & Johnson's return on equity of 32.60% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Johnson & Johnson	21.83%	32.60%	13.29%

Johnson & Johnson has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$41.94M	2.00	-$2.84M	-$0.49	N/A
Johnson & Johnson	$96.36B	5.59	$26.80B	$8.65	25.85

Cumberland Pharmaceuticals has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

In the previous week, Johnson & Johnson had 85 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 89 mentions for Johnson & Johnson and 4 mentions for Cumberland Pharmaceuticals. Johnson & Johnson's average media sentiment score of 1.02 beat Cumberland Pharmaceuticals' score of 0.59 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Johnson & Johnson	60 Very Positive mention(s)	9 Positive mention(s)	11 Neutral mention(s)	6 Negative mention(s)	3 Very Negative mention(s)	Positive

Johnson & Johnson has a consensus target price of $253.04, suggesting a potential upside of 13.17%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts plainly believe Johnson & Johnson is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Johnson & Johnson beats Cumberland Pharmaceuticals on 15 of the 16 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to AbbVie?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

AbbVie has a net margin of 5.79% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Cumberland Pharmaceuticals' return on equity of -12.01% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
AbbVie	5.79%	-576.45%	13.39%

Cumberland Pharmaceuticals has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

AbbVie has a consensus price target of $253.43, indicating a potential upside of 16.66%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

AbbVie has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$41.94M	2.00	-$2.84M	-$0.49	N/A
AbbVie	$61.16B	6.28	$4.23B	$2.03	107.02

In the previous week, AbbVie had 43 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 47 mentions for AbbVie and 4 mentions for Cumberland Pharmaceuticals. AbbVie's average media sentiment score of 0.92 beat Cumberland Pharmaceuticals' score of 0.59 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	28 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

AbbVie beats Cumberland Pharmaceuticals on 15 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Merck & Co., Inc.?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Cumberland Pharmaceuticals has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Merck & Co., Inc. has a net margin of 13.59% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Merck & Co., Inc.'s return on equity of 27.55% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Merck & Co., Inc.	13.59%	27.55%	10.73%

Merck & Co., Inc. has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$41.94M	2.00	-$2.84M	-$0.49	N/A
Merck & Co., Inc.	$65.01B	4.37	$18.25B	$3.55	32.37

Merck & Co., Inc. has a consensus price target of $128.18, suggesting a potential upside of 11.53%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.68

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Merck & Co., Inc. had 60 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 64 mentions for Merck & Co., Inc. and 4 mentions for Cumberland Pharmaceuticals. Merck & Co., Inc.'s average media sentiment score of 1.03 beat Cumberland Pharmaceuticals' score of 0.59 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Merck & Co., Inc.	43 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Positive

Summary

Merck & Co., Inc. beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Pfizer?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Pfizer has a consensus target price of $28.82, suggesting a potential upside of 13.64%. Given Pfizer's stronger consensus rating and higher possible upside, analysts plainly believe Pfizer is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pfizer	3 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.20

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 0.6% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cumberland Pharmaceuticals has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Pfizer has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$41.94M	2.00	-$2.84M	-$0.49	N/A
Pfizer	$63.31B	2.28	$7.77B	$1.31	19.36

Pfizer has a net margin of 11.83% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Pfizer's return on equity of 19.44% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Pfizer	11.83%	19.44%	8.41%

In the previous week, Pfizer had 77 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 81 mentions for Pfizer and 4 mentions for Cumberland Pharmaceuticals. Pfizer's average media sentiment score of 0.63 beat Cumberland Pharmaceuticals' score of 0.59 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	34 Very Positive mention(s)	17 Positive mention(s)	13 Neutral mention(s)	10 Negative mention(s)	7 Very Negative mention(s)	Positive

Summary

Pfizer beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.

Get Cumberland Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPIX vs. The Competition

Export

Metric	Cumberland Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$84.06M	$2.91B	$6.25B	$12.42B
Dividend Yield	N/A	1.79%	2.69%	5.29%
P/E Ratio	-11.45	17.69	22.29	24.19
Price / Sales	2.00	739.65	581.44	138.36
Price / Cash	15.54	56.38	42.31	57.88
Price / Book	3.42	3.85	9.84	6.72
Net Income	-$2.84M	$75.85M	$3.57B	$337.19M
7 Day Performance	-4.27%	-1.68%	-1.17%	0.48%
1 Month Performance	28.67%	22.17%	3.84%	5.06%
1 Year Performance	-2.94%	21.83%	27.39%	34.27%

Cumberland Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPIX Cumberland Pharmaceuticals	0.685 of 5 stars	$5.61 -2.8%	N/A	+1.1%	$84.06M	$41.94M	N/A	80	News Coverage
LLY Eli Lilly and Company	4.5794 of 5 stars	$1,066.77 +0.2%	$1,227.00 +15.0%	+42.6%	$1.00T	$65.18B	37.90	50,000	Trending News
JNJ Johnson & Johnson	4.4837 of 5 stars	$230.37 -1.7%	$253.04 +9.8%	+43.5%	$564.11B	$94.19B	26.63	138,200	Trending News
ABBV AbbVie	4.8233 of 5 stars	$212.79 -1.3%	$253.43 +19.1%	+15.5%	$381.10B	$61.16B	104.82	57,000	Trending News
MRK Merck & Co., Inc.	4.4731 of 5 stars	$119.75 -2.2%	$128.18 +7.0%	+52.0%	$302.33B	$65.77B	33.73	75,000	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CPIX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. LLY, JNJ, ABBV, MRK, and PFE

How does Cumberland Pharmaceuticals compare to Eli Lilly and Company?

Summary

How does Cumberland Pharmaceuticals compare to Johnson & Johnson?

Summary

How does Cumberland Pharmaceuticals compare to AbbVie?

Summary

How does Cumberland Pharmaceuticals compare to Merck & Co., Inc.?

Summary

How does Cumberland Pharmaceuticals compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. LLY, JNJ, ABBV, MRK, and PFE

How does Cumberland Pharmaceuticals compare to Eli Lilly and Company?

Is LLY or CPIX more profitable?

Do insiders and institutionals have more ownership in LLY or CPIX?

Do analysts rate LLY or CPIX?

Does the media refer more to LLY or CPIX?

Which has higher earnings and valuation, LLY or CPIX?

Which has more volatility and risk, LLY or CPIX?

Summary

How does Cumberland Pharmaceuticals compare to Johnson & Johnson?

Is CPIX or JNJ more profitable?

Which has better valuation and earnings, CPIX or JNJ?

Which has more volatility and risk, CPIX or JNJ?

Does the media prefer CPIX or JNJ?

Do analysts rate CPIX or JNJ?

Do institutionals and insiders have more ownership in CPIX or JNJ?

Summary

How does Cumberland Pharmaceuticals compare to AbbVie?

Do insiders and institutionals hold more shares of CPIX or ABBV?

Is CPIX or ABBV more profitable?

Which has more risk and volatility, CPIX or ABBV?

Do analysts rate CPIX or ABBV?

Which has higher valuation and earnings, CPIX or ABBV?

Does the media refer more to CPIX or ABBV?

Summary

How does Cumberland Pharmaceuticals compare to Merck & Co., Inc.?

Which has more risk & volatility, CPIX or MRK?

Is CPIX or MRK more profitable?

Which has stronger valuation and earnings, CPIX or MRK?

Do analysts rate CPIX or MRK?

Do insiders & institutionals have more ownership in CPIX or MRK?

Does the media refer more to CPIX or MRK?

Summary

How does Cumberland Pharmaceuticals compare to Pfizer?

Do analysts rate CPIX or PFE?

Do insiders and institutionals have more ownership in CPIX or PFE?

Which has more risk and volatility, CPIX or PFE?

Which has better earnings & valuation, CPIX or PFE?

Is CPIX or PFE more profitable?

Does the media prefer CPIX or PFE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools